News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Guggenheim reiterated a Buy rating for Argenx Se (ARGX) with a price target of $1,135.00, according to an analyst report. This recommendation is supported by analyst Yatin Suneja's strong track record and a general "Strong Buy" consensus for ARGX with an average price target …
Sharemaestro market context Trend signal active 52 weeks +29.0% · Next-week setup positive 56.3%Argenx stock has shown stability following strong revenue growth in 2025, with total revenue reaching EUR 2.13 billion, a 93% increase from 2024. The company also turned profitable, reporting diluted earnings per share of EUR 1.74 compared to a loss in the previous year, …
Argenx stock shows stability as investors evaluate the strong revenue growth of its autoimmune therapy, Vyvgart, and the company's substantial cash reserves. The article details Vyvgart's impressive revenue increase in FY 2023, significant cash position, and ongoing clinical pipeline developments aimed at expanding the …
Sharemaestro market context Trend signal active 52 weeks +29.0% · Next-week setup positive 56.3%Kuehn Law is investigating Regenxbio, Inc. over allegations of providing false or misleading information regarding the safety and efficacy of its gene therapy trial for Hurler Syndrome. The lawsuit claims Regenxbio made overly positive statements about the trial's success based on Phase I/II study …
Kuehn Law, PLLC is investigating whether officers and directors of Regenxbio, Inc. (NASDAQ: RGNX) breached their fiduciary duties to shareholders. This investigation stems from a federal securities lawsuit alleging that Regenxbio provided false information regarding its RGX-111 trial study, specifically concerning its efficacy and …
Argenx stock is trading steadily following a mix of rising Q1 2026 revenue and continued clinical progress with its drug Vyvgart. The company reported a significant increase in total revenue for Q1 2026, primarily driven by Vyvgart sales, while also maintaining high investment in …
This article reports on an 8-K filing by REGENXBIO Inc. on July 20, 2026, detailing other events. It also highlights a research report on fuel-cell deployments at U.S. data centers, indicating 154 MW of operating capacity and 6.31 GW in proposed projects across various …
Argenx stock performance is characterized by the strong revenue growth of its drug Vyvgart, which underpins the company's financial outlook despite widening operating losses due to significant R&D investments. The company is transitioning from a development-stage biotech to a commercial-stage entity, with Vyvgart sales …
Regenxbio reported five-year durability for its gene therapy, surabgene lomparvovec (sura-vec), showing stable to improved vision in patients with wet AMD after a single subretinal dose. These long-term results come ahead of pivotal Phase III data in Q4 2026, which will compare sura-vec against …
Argenx stock is trading near recent highs, supported by strong revenue growth driven primarily by its autoimmune therapy Vyvgart. While the company is experiencing significant top-line expansion, operating expenses are also rising due to global launches and clinical development, leading to wider operating losses. …
Sharemaestro market context Trend signal active 52 weeks +29.0% · Next-week setup positive 56.3%REGENXBIO Inc. has priced an underwritten public offering of 10,003,889 shares of common stock at $9.00 per share and 1,111,111 pre-funded warrants at $8.9999 per warrant, expecting to net approximately $107.8 million after expenses, including the full exercise of the underwriters' 30-day option for …
Argenx stock is holding steady as investors consider the company's strong revenue growth, driven by its lead autoimmune therapy, and its ongoing investments in a deep immunology pipeline. The company's financial health, including substantial cash reserves, supports its capital-intensive R&D efforts. Future growth is …
Argenx stock is holding steady, driven by strong growth in immunology revenue, particularly from its FcRn antibody franchise. The company reported double-digit top-line growth in Q1 2025 and 70% revenue increase in fiscal 2024, despite continued net losses due to heavy R&D investment. With …
Argenx stock performance is influenced by the rapid revenue growth of its drug Vyvgart, primarily in autoimmune neuromuscular indications, and its substantial cash reserves funding an extensive clinical pipeline. The company reported a more than threefold increase in total revenue in 2023, reaching approximately …
REGENXBIO Inc. announced positive long-term data for its investigational gene therapy, surabgene lomparvovec (sura-vec), for wet Age-related Macular Degeneration (AMD) and diabetic retinopathy (DR). The data, presented at the ASRS Annual Meeting, showed durable efficacy and safety through five years for wet AMD patients …
REGENXBIO Inc. (RGNX) stock dropped by 11.92% after announcing a $100 million public offering of common stock and pre-funded warrants at $9.00 per share to fund operations and pipeline development. This equity raise, coupled with a shareholder litigation firm investigating alleged misleading statements about …
REGENXBIO Inc. (NASDAQ: RGNX) is conducting a primary offering of 10,003,889 shares of common stock and 1,111,111 pre-funded warrants for a total public offering price of $100 million. The public offering price is $9.00 per share and $8.9999 per warrant, with underwriters having a …
Regenxbio Inc. (RGNX) announced a public offering of common stock and pre-funded warrants aimed at raising approximately $100 million to support its gene therapy research and development. The company, which has a market cap of $579.01 million, has a GF Score of 60, indicating …
REGENXBIO Inc. (RGNX) stock is down over 9% following news of a planned $100 million public offering of common stock and a pending investigation into its officers and directors over alleged misleading statements related to a gene therapy trial. The offering aims to fund …
Regenxbio (RGNX) announced a public offering of $100 million in common stock and pre-funded warrants. This financial move led to a significant 10% decline in the company's shares during after-hours trading. The offering includes standard stock and warrants, which can be exercised at a …
REGENXBIO Inc. (RGNX) stock experienced a significant dip due to a bearish sentiment following a planned $100M public offering of common stock and ongoing shareholder litigation. The equity offering aims to fund its late-stage gene therapy pipeline but introduces dilution, while the lawsuit concerns …
REGENXBIO Inc. (Nasdaq: RGNX) announced a proposed underwritten public offering to raise $100 million for its gene therapy pipeline. This funding comes as the company advances multiple late-stage programs, including RGX-202 for Duchenne muscular dystrophy and RGX-121 for Hunter syndrome, towards potential regulatory decisions …
Argenx stock is trading near record levels after reporting strong growth in Q1 2026, with total revenue up 33% to $532 million and net income doubling. The company's financial health is also bolstered by a 2024 oncology collaboration and its flagship Vyvgart antibody therapy, …
REGENXBIO Inc. has priced an underwritten public offering of common stock and pre-funded warrants at $9 per share, aiming to raise approximately $100.0 million. This capital raise comes after a nearly 20% stock decline and a reported negative free cash flow of $236 million …
REGENXBIO Inc. (RGNX) shares dropped 15% after-hours following the announcement of a $100 million public stock offering, sparking dilution concerns among investors. The company, which specializes in gene therapies for rare diseases, has not specified how the new funds will be utilized but typically …
REGENXBIO Inc. (NASDAQ: RGNX) plans a primary offering of $100 million in common stock to fund general corporate purposes, including clinical trials and pipeline development. The company anticipates receiving a $100 million milestone payment from AbbVie in July 2026 and expects its total cash …
REGENXBIO Inc. (NASDAQ:RGNX) announced a $100 million public offering of common stock, which will be underwritten by Morgan Stanley, J.P. Morgan, Leerink Partners, and Mizuho. The company, focused on gene therapy for rare and retinal diseases, is rapidly burning through cash, with a negative …
REGENXBIO has filed a prospectus with the SEC for a common stock offering that could raise up to $100 million. The filing is a standard procedure that allows the company flexibility in future fundraising efforts. This move indicates potential plans to finance ongoing operations, …
REGENXBIO Inc. announced its intention to offer and sell $100 million of its common stock in an underwritten public offering, contingent on market conditions. The company also plans to grant underwriters a 30-day option to purchase up to an additional 15% of the shares …
Argenx stock is holding steady, driven by the strong revenue growth of its Vyvgart therapy for autoimmune diseases, which has seen double-digit and even triple-digit increases. Despite rapid top-line growth, the company continues to report operating losses due to significant investments in its autoimmune …
Sharemaestro market context Trend signal active 52 weeks +29.0% · Next-week setup positive 56.3%argenx announced that it will host a conference call and audio webcast on Thursday, July 23, 2026, at 2:30 p.m. CET (8:30 a.m. ET) to discuss its half-year 2026 financial results and provide a second-quarter business update. The webcast will be accessible on the …
argenx (Euronext & Nasdaq: ARGX) announced it will host a conference call and audio webcast on Thursday, July 23, 2026, at 2:30 p.m. CET (8:30 a.m. ET). The company will discuss its half-year 2026 financial results and provide a second-quarter business update. Investors can …
Sharemaestro market context Trend signal active 52 weeks +29.0% · Next-week setup positive 56.3%The ADR gained 5.9% in the latest week and sits just 1.5% below its 52-week high, but the move lacks volume confirmation and carries a stretched premium to Sharemaestro Fair Value.
Search by ticker symbol or company name and select a result to open its chart.